Current Report Filing (8-k)
March 08 2018 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
March 8, 2018
BIOSCRIP, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-11993
|
05-0489664
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(Employer Identification Number)
|
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(720) 697-5200
(Registrant's telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02. Results of Operations and
Financial Condition.
On March 8, 2018, BioScrip, Inc. (the “Company”)
issued a press release reporting its fourth quarter and full-year 2017 financial results. A copy of the press release is furnished
with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The press release includes certain non-GAAP
financial measures as described therein. As required by Regulation G, reconciliation between any non-GAAP financial measures presented
and the most directly comparable GAAP financial measures is also provided.
Item 8.01. Other Events.
As previously announced, the Company will
host a conference call to discuss its fourth quarter and full-year 2017 financial results on March 8, 2018, at 9:00 Eastern Time.
Interested parties may participate in the conference call by dialing 888-372-9592 (U.S.) or by accessing a link on the Company’s
website at
www.bioscrip.com
5-10 minutes prior to the start of the call. A replay of the conference call will
be available for one week after the call’s completion by dialing 855-859-2056 (U.S.) and entering conference call ID number
5266355. An audio webcast and archive will also be available for 30 days under the “Investor Relations” section of
the Company’s website.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
As provided in General Instruction B.2
to Form 8-K, the information furnished in Item 2.02 and in Exhibit 99.1 hereto, as it relates to the Company’s financial
results for the quarter and year ended December 31, 2017, shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under
that Section and shall not be deemed incorporated by reference into any filing of the Company with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly provided by specific
reference in such filing.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
Date: March 8, 2018
|
By:
|
/s/ Kathryn M. Stalmack
|
|
|
Kathryn M. Stalmack
|
|
|
Senior Vice President, General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024